ResMed Inc. (RMD) FY2027 Q1 P&L / Income Statement

Published · Updated Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

Key Takeaways

  • Net income rose $69.88 M to $418.41 M, but a $54.92 M after-tax gain supplied 79% of it.
  • Operating income rose only 1.4%, to $452.98 M, while net income rose 20%.
  • Gross margin edged up to 61.5%, helped partly by lower amortization after the MatrixCare sale.
  • Selling, general and administrative costs rose to 22.2% of sales, from 21.1% a year earlier.
  • Other income, net, supplied $86.17 M this quarter, against $0.26 M a year earlier.

The Unvarnished Truth

A one-time gain carried most of ResMed's 20% profit jump.

Net income rose 20% to $418.41 M, and that headline reads like a turnaround. The engine underneath is smaller. Operating income, the profit from the main business before interest and gains, rose only 1.4%, to $452.98 M. The gap was filled by a $61.78 M gain on the sale of MatrixCare, which the filing calls non-recurring. After tax, that gain is $54.92 M, which accounts for 79% of the rise in net income.

Tax did not help. The effective rate rose to 22.4% from 22.0%, and the filing points to global minimum taxes and discrete items. Spending moved up too: research and development rose 15% to $102.86 M, and selling, general and administrative costs rose 12% to $314.72 M. The filing's gross margin story is tied to the sale too: the MD&A credits lower amortization of acquired intangibles after MatrixCare, which means a piece of the margin gain comes from the sale rather than the core.

Sales grew 6% this quarter, and the profit that outran them was booked from a sale, not from selling more. The company's own non-GAAP figure strips the gain and adds back restructuring and amortization, and it shows net income of $418.01 M, about 11% above a year earlier. The next quarter without a gain is the real test. Without the MatrixCare gain, what will profit look like if research and selling costs keep climbing faster than sales?

Revenue by Product and Service

Swipe to see the full flow
ResMed Inc. (RMD) FY2027 Q1 P&L / Income StatementIncome statement for 2026-07-01 through 2026-09-30. View: Product and service. Revenue and costs use their disclosed categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETSleep and Breathing Health revenueResidential Care Software revenueNet revenueGross profitCost of salesSleep and Breathing Health cost of revenueResidential Care Software cost of revenueIncome from operationsTotal operating expensesTotal operating expensesTotal other income (loss), netIncome before income taxesNet incomeIncome taxesTotal other income (loss), netTotal other income(loss), net$86.17 MIncome before income taxesPretax income$539.16 MNet revenueNet revenue$1.41 BGross profitGross profit$870.57 MIncome from operationsIncome from operations$452.98 MNet incomeNet income$418.41 MSleep and Breathing Health revenueSleep and Breathing Health$1.26 BTotal operating expensesTotal operatingexpenses$417.58 MIncome taxesIncome taxes$120.74 MTotal operating expensesTotal operating expenses$417.58 MCost of salesCost of sales$544.25 MResidential Care Software revenueResidential Care Software$155.01 MSleep and Breathing Health cost of revenueSleep and BreathingHealth cost$493.88 MResidential Care Software cost of revenueResidential CareSoftware cost$50.37 M
Chart details

ResMed Inc. (RMD) FY2027 Q1 P&L / Income Statement

Income statement for 2026-07-01 through 2026-09-30. View: Product and service. Revenue and costs use their disclosed categories.

Net revenue
1,414,814,000 US dollars
Cost of sales
544,247,000 US dollars
Gross profit
870,567,000 US dollars
Total operating expenses
417,583,000 US dollars
Income from operations
452,984,000 US dollars
Total other income (loss), net
86,171,000 US dollars
Income before income taxes
539,155,000 US dollars
Income taxes
120,742,000 US dollars
Net income
418,413,000 US dollars
Sleep and Breathing Health revenue
1,259,802,000 US dollars
Residential Care Software revenue
155,012,000 US dollars
Sleep and Breathing Health cost of revenue
493,879,000 US dollars
Residential Care Software cost of revenue
50,368,000 US dollars
Total operating expenses
417,583,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
ResMed Inc. (RMD) FY2027 Q1 P&L / Income Statement Sankey chart, Product and service view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Intelligent Insights for Investors

How much of ResMed's profit comes from its main business?

About 84% of it: its main business earned $452.98 M this quarter, and interest, investments and other items, led by gain on divestment of subsidiaries, added the rest.

Did a lower tax rate drive ResMed's profit growth?

No: its tax rate rose to 22.4% this quarter from 22.0% a year earlier. Profit after tax therefore grew more slowly than profit before income taxes.

Is ResMed investing more or less in research and equipment than before?

It is spending more on both, as a share of sales: research and development came to 7.3% of sales this quarter (6.7% a year earlier), and property and equipment spending came to 3.4% (3.2% a year earlier).

Intelligent Insights for Lenders

Does ResMed earn enough to cover its interest payments?

Yes: its operating profit covered its interest 94.1 times this quarter, against 62.7 times a year earlier.

Intelligent Insights for Employees

Are ResMed's overhead and selling costs falling as a share of sales?

No: selling and overhead costs took 22.2% of sales this quarter, up from 21.1% a year earlier.

Intelligent Insights for Customers

What does ResMed sell, and how much of each?

Above all, Sleep and Breathing Health, at 89% of sales this quarter. Next is Residential Care Software, at 11%.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!